Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.02, Zacks reports. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%.
Lifecore Biomedical Price Performance
Shares of NASDAQ LFCR traded down $0.77 during mid-day trading on Thursday, hitting $6.66. 857,843 shares of the stock traded hands, compared to its average volume of 214,029. Lifecore Biomedical has a twelve month low of $3.68 and a twelve month high of $8.90. The firm has a 50 day simple moving average of $6.96 and a two-hundred day simple moving average of $5.77. The company has a debt-to-equity ratio of 12.90, a current ratio of 1.83 and a quick ratio of 0.80. The company has a market cap of $245.27 million, a PE ratio of 83.25 and a beta of 0.99.
Analyst Upgrades and Downgrades
Separately, Craig Hallum lifted their price target on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the company a "buy" rating in a report on Friday, November 22nd.
Get Our Latest Analysis on LFCR
About Lifecore Biomedical
(
Get Free Report)
Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.
Featured Articles
Before you consider Lifecore Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifecore Biomedical wasn't on the list.
While Lifecore Biomedical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
